All Cancer articles – Page 13
-
ArticleCancer drug discovery: protein-ligand interactions
Dr Rob van Montfort, a leading researcher at the Centre for Cancer Drug Discovery (CCDD) within The Institute of Cancer Research, London, is at the forefront of cancer drug discovery. Focusing on protein-ligand interactions, his work utilises structural biology and biochemical methods to help the discovery of novel small-molecule drugs ...
-
NewsNew biomarker advances cancer treatments
Researchers have discovered ways to enhance NIR-PIT to ensure tumours are treated sufficiently and improve patient outcomes.
-
NewsMachine could make CAR T-cell therapy more accessible
Researchers have developed a new bioreactor that can manufacture T cells faster than other technologies, which may advance immunotherapy.
-
NewsKey epitope can trigger tumour cell death
An epitope on CD95 receptor causes tumour cells to self-destruct and may prolong benefits of CAR T-cell therapy for solid tumours.
-
NewsCancer-killing T cells enhanced by engineered bacteria
Bacteria programmed to paint targets on solid tumours for T cells to see eliminates the need for specific antigens.
-
ArticleNovel method for early cancer diagnosis
A recent scientific collaboration, led by the Institute of Nuclear Physics of the Polish Academy of Sciences, has overcome measurement challenges, enabling reliable cancer diagnosis.
-
NewsHuman-derived proteins used in DREAM tool
CRISPR-DREAM tool used to activate insufficiently expressed genes and convert skin cells to induced pluripotent stem cells (iPSCs).
-
ArticleInsights into the critical initial phase of embryonic development
Researchers from the University of Helsinki and the National Institutes of Health (NIH) in the United States have made a new discovery: the ectoderm, one of the germ layers, does not lose its pluripotency during gastrulation, contrary to prior beliefs.
-
ArticleSRC-3: CoRegen's revolutionary approach to cancer
Drug Target Review’s Taylor Mixides exclusively interviews David Lonard, PhD, Chief Scientific Officer at CoRegen and Associate Professor at Baylor University, to uncover the mechanisms of SRC-3 and why it’s key to targeting cancer – and only cancer.
-
NewsChildhood cancer survivors’ mortality risk
Researchers find genetic explanation for increased risk of developing second cancers.
-
NewsProteolysis: new method developed to target cancer cells
Researchers have found that targeting chimeras with click-release proteolysis activates specific molecules that target cancer cells without harming health cells.
-
NewsSenescent immune cells promote lung tumour growth
A recent study sheds light on an unexpected discovery concerning macrophages, a vital type of white blood cell in the body's defence against infections and tumours.
-
News
Novel approach to overcome resistance to cancer drugs
Researchers at the University of Queensland have discovered a promising drug target capable of addressing drug resistance and preventing tumour regrowth in cancer patients.
-
NewsEngineered immune cells for improved cancer defence
A collaborative team has uncovered a method to extend the functionality of CAR-T cells.
-
NewsCancer inhibitors shows success in slowing tumour growth
Researchers have successfully demonstrated the potential of using a combination of inhibitors to effectively curb tumour growth and stave off relapses in patients afflicted with specific cancers.
-
ArticleBioengineered instrument reveals hidden cancer cells
Scientists at Stanford University have engineered a biomolecule that can specifically remove mucins from cancer cells. This breakthrough could have a significant impact on future cancer therapies.
-
ArticleNew research holds significance in regulating T cell function
New research shows T cells use the nuclear receptor RARα not just for gene regulation, but also to trigger cell surface events that activate them against pathogens and cancer.
-
ArticleTherapeutic frontiers: the potential of RRx-001 and AdAPT-001
Meet RRx-001 (nibrozetone) and AdAPT-001—two cutting-edge compounds crafted by EpicentRx. In this Q&A session with Dr Bryan Oronsky, Chief Development Officer at EpicentRx, we discover novel mechanisms, diverse applications, and game-changing impact on cancer treatment and beyond.
-
NewsImmunotherapy: antibody set for combating tumours
A recent study sheds light on the potential of artificial DNA structures that, when combined with antibodies, guide the immune system to target cancer cells specifically.
-
ArticleCancer immunotherapy: GDF-15's role in Anti-PD-1 resistance
In this interview with Christine Schuberth-Wagner, Chief Scientific Officer at CatalYm, we discover research uncovering a central factor contributing to anti-PD-1 resistance in cancer immunotherapy.